| Dr Martin David Broff, MD | |
|
851 Main St, South Weymouth, MA 02190-1612 | |
| (781) 331-1060 | |
| (781) 335-9852 |
| Full Name | Dr Martin David Broff |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 48 Years |
| Location | 851 Main St, South Weymouth, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043208192 | NPI | - | NPPES |
| C27088 | Other | MA | BLUE CROSS BLUE SHIELD |
| 2088649 | Medicaid | MA | |
| 1005 | Other | MA | HARVARD PILGRIM |
| 044319 | Other | MA | TUFTS HEALTH CARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 44319 (Massachusetts) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| South Shore Allergy And Asthma Specialists P.c. | 6204854953 | 3 |
News Archive
IRIN/PlusNews has profiled the Rwanda-based initiative Nkund'abana - which stands for "I love children in Kinyarwanda" - that involves local community members in raising children whose parents or guardians have died of AIDS-related illnesses.
Inside the Mizzou Asphalt Pavement and Innovation Lab at the University of Missouri College of Engineering, Bill Buttlar normally leads a research team developing innovative ways to build better roads and stronger bridges.
Pharmacoeconomic methods rank low as a decision influencer on formulary changes, according to a new survey released today by the Society of Hospital Medicine and the American Society of Health-System Pharmacists. Respondents reported that only 13 percent of formulary system decisions made by Pharmacy and Therapeutics committees in hospitals is influenced by pharmacoeconomic methods.
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
State Sen. Emmett Hanger seeks a compromise on the issue that threatens to shut down the state government because it has deadlocked negotiations on the budget.
› Verified 8 days ago
| Entity Name | Children's Hospital Pediatric Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457306664 PECOS PAC ID: 3476541830 Enrollment ID: O20040504000964 |
News Archive
IRIN/PlusNews has profiled the Rwanda-based initiative Nkund'abana - which stands for "I love children in Kinyarwanda" - that involves local community members in raising children whose parents or guardians have died of AIDS-related illnesses.
Inside the Mizzou Asphalt Pavement and Innovation Lab at the University of Missouri College of Engineering, Bill Buttlar normally leads a research team developing innovative ways to build better roads and stronger bridges.
Pharmacoeconomic methods rank low as a decision influencer on formulary changes, according to a new survey released today by the Society of Hospital Medicine and the American Society of Health-System Pharmacists. Respondents reported that only 13 percent of formulary system decisions made by Pharmacy and Therapeutics committees in hospitals is influenced by pharmacoeconomic methods.
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
State Sen. Emmett Hanger seeks a compromise on the issue that threatens to shut down the state government because it has deadlocked negotiations on the budget.
› Verified 8 days ago
| Entity Name | South Shore Allergy & Asthma Specialists P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952361503 PECOS PAC ID: 6204854953 Enrollment ID: O20051110000664 |
News Archive
IRIN/PlusNews has profiled the Rwanda-based initiative Nkund'abana - which stands for "I love children in Kinyarwanda" - that involves local community members in raising children whose parents or guardians have died of AIDS-related illnesses.
Inside the Mizzou Asphalt Pavement and Innovation Lab at the University of Missouri College of Engineering, Bill Buttlar normally leads a research team developing innovative ways to build better roads and stronger bridges.
Pharmacoeconomic methods rank low as a decision influencer on formulary changes, according to a new survey released today by the Society of Hospital Medicine and the American Society of Health-System Pharmacists. Respondents reported that only 13 percent of formulary system decisions made by Pharmacy and Therapeutics committees in hospitals is influenced by pharmacoeconomic methods.
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
State Sen. Emmett Hanger seeks a compromise on the issue that threatens to shut down the state government because it has deadlocked negotiations on the budget.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Martin David Broff, MD 851 Main St, South Weymouth, MA 02190-1612 Ph: (781) 331-1060 | Dr Martin David Broff, MD 851 Main St, South Weymouth, MA 02190-1612 Ph: (781) 331-1060 |
News Archive
IRIN/PlusNews has profiled the Rwanda-based initiative Nkund'abana - which stands for "I love children in Kinyarwanda" - that involves local community members in raising children whose parents or guardians have died of AIDS-related illnesses.
Inside the Mizzou Asphalt Pavement and Innovation Lab at the University of Missouri College of Engineering, Bill Buttlar normally leads a research team developing innovative ways to build better roads and stronger bridges.
Pharmacoeconomic methods rank low as a decision influencer on formulary changes, according to a new survey released today by the Society of Hospital Medicine and the American Society of Health-System Pharmacists. Respondents reported that only 13 percent of formulary system decisions made by Pharmacy and Therapeutics committees in hospitals is influenced by pharmacoeconomic methods.
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
State Sen. Emmett Hanger seeks a compromise on the issue that threatens to shut down the state government because it has deadlocked negotiations on the budget.
› Verified 8 days ago
Dr. Michael C. Young, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 851 Main St, South Weymouth, MA 02190 Phone: 781-331-1060 Fax: 781-335-9852 | |
Mrs. Margaret Ann Vallen Mashikian, M.D. Allergy & Immunology Medicare: May Accept Medicare Assignments Practice Location: 851 Main St, Suite 21, South Weymouth, MA 02190 Phone: 781-331-1060 |